Biotech | April 20, 2026
FDA pushes forward on gene-editing therapies with new safety roadmap
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence
Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
The company allocated €56 million to research and development for next-generation line solutions
Integrated eCOA technology and rater training aim to reduce variability and strengthen ClinRO outcomes
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
Subscribe To Our Newsletter & Stay Updated
